Here are four out of 14 stocks: Urban Outfitters: The Zacks Rank #1 company is a lifestyle specialty retailer that offers fashion apparel ... Pfizer’s Biopharma reporting segment comprises ...

We came across a bullish thesis on Mereo BioPharma Group plc (MREO) on Substack by Jake LaMotta. In this article, we will summarize the bulls’ thesis on MREO. Mereo BioPharma Group plc (MREO)'s ...

Cue Biopharma, Inc. BOSTON, April 14, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to ...

Boehringer Ingelheim and Cue Biopharma, Inc. (Nasdaq: CUE) today announced a strategic research collaboration and license agreement to develop and commercialize Cue Biopharma’s CUE-501 product ...

Q1 biopharma layoff trends, plus expectations for Q2 By Ayla Ellison, Gabrielle Masson, Andrea Park Apr 11, 2025 9:25am The Top Line layoffs Cell & Gene Therapy biopharma industry ...

Boehringer Ingelheim and Cue Biopharma (CUE) announced a strategic research collaboration and license agreement to develop and commercialize Cue Biopharma’s CUE-501 product candidate ...

Ingelheim, Germany, and Boston, MA, USA, April 14, 2025 – Boehringer Ingelheim and Cue Biopharma, Inc. (Nasdaq: CUE) today announced a strategic research collaboration and license agreement to ...

Scott Lyman, CEO of Belhaven Biopharma, expressed enthusiasm about the results, stating, "The successful outcomes of this dose confirmation and allergic rhinitis study clears the way for our pivotal ...

U.S. tariffs on biopharmaceuticals have advanced beyond administration talking points.As a precursor to tariffs, Commerce Secretary Howard Lutnick initiated an investigation under section 232 of the ...

Cue Biopharma (CUE) announced that it is commencing an underwritten public offering of shares of its common stock and accompanying warrants to purchase shares of common stock. All of the ...

INGELHEIM, Germany and BOSTON, April 14, 2025 (GLOBE NEWSWIRE) -- Boehringer Ingelheim and Cue Biopharma, Inc. (Nasdaq: CUE) today announced a strategic research collaboration and license ...

(RTTNews) - Boehringer Ingelheim and Cue Biopharma, Inc. (CUE), Tuesday, announced a strategic research collaboration and license agreement to develop and commercialize CUE-501. Cue Biopharma's ...